Global

As drug prices in the US fluctuate, pharma companies may look to other regions for opportunity.

The company announced the plans as President visited the UK.

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Sources say the President’s focus has shifted.

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

The letter states that the companies have 60 days to meet the President's requirements.

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

The GMRLN plays an important role in identifying outbreaks early and providing the necessary support to control them.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Arda Ural discusses the possible impact on how companies plan for growth based on the impact of the tariffs.

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Arda Ural discusses the different ways that companies may change the ways they allocate resources in the current geopolitical climate.

Lynlee Brown, partner at EY, discusses the impacts that the tariffs have across various regions.

Arda Ural explains how the tariffs will impact profit margins and potentially cause drug shortages.

Four tips for midsized companies when entering new global markets.

The pharmaceutical company had previously been subjected to a 2-year suspension.

Pharma companies face unique challenges with market access in this region.

Three of the new sites will focus primarily on producing ingredients for domestic usage.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.